Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Get Free Report) fell 3.9% on Friday . The company traded as low as $0.13 and last traded at $0.13. 603,676 shares were traded during mid-day trading, a decline of 46% from the average session volume of 1,122,745 shares. The stock had previously closed at $0.13.
Analysts Set New Price Targets
A number of brokerages have weighed in on TCRT. Laidlaw downgraded shares of Alaunos Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, August 15th. HC Wainwright cut shares of Alaunos Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 16th.
Alaunos Therapeutics Stock Performance
Alaunos Therapeutics (NASDAQ:TCRT – Get Free Report) last issued its quarterly earnings data on Monday, August 14th. The company reported ($0.04) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.04). As a group, equities research analysts predict that Alaunos Therapeutics, Inc. will post -0.15 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC grew its holdings in Alaunos Therapeutics by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 2,094,338 shares of the company’s stock valued at $1,359,000 after purchasing an additional 17,840 shares during the period. CIBC Private Wealth Group LLC grew its holdings in Alaunos Therapeutics by 65.8% during the first quarter. CIBC Private Wealth Group LLC now owns 50,400 shares of the company’s stock valued at $32,000 after purchasing an additional 20,000 shares during the period. UBS Group AG boosted its holdings in shares of Alaunos Therapeutics by 7.6% in the third quarter. UBS Group AG now owns 288,597 shares of the company’s stock valued at $496,000 after buying an additional 20,422 shares during the period. Magnolia Capital Advisors LLC boosted its holdings in shares of Alaunos Therapeutics by 5.6% in the first quarter. Magnolia Capital Advisors LLC now owns 448,469 shares of the company’s stock valued at $283,000 after buying an additional 23,650 shares during the period. Finally, BNP Paribas Arbitrage SNC boosted its holdings in shares of Alaunos Therapeutics by 67.5% in the third quarter. BNP Paribas Arbitrage SNC now owns 58,847 shares of the company’s stock valued at $101,000 after buying an additional 23,704 shares during the period. Institutional investors and hedge funds own 27.72% of the company’s stock.
About Alaunos Therapeutics
Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor engine.
- Five stocks we like better than Alaunos Therapeutics
- How Can Investors Use the Dogs of the Dow Strategy?
- The Best 5 Small Cap AI Companies to Buy Now
- The Dividend Kings With Highest Yield
- Miso Robotics Stock: Is an IPO Coming Soon?
- Earnings Per Share Calculator: How to Calculate EPS
- 3 Stocks to Play the Easing Food Supply Chain
Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.